<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Overview of the included studies</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Domain</th>
    <th>No. of extracted studies</th>
    <th>Setting*</th>
    <th>No. of participants</th>
    <th>Populations</th>
    <th>Study objectives</th>
    <th>Intervention</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Clinical phenotype and natural history of disease</td>
    <td>25</td>
    <td>
     <p>14 Nigeria</p>
     <p>7 Sierra Leone</p>
     <p>3 Liberia</p>
     <p>3 Mali</p>
     <p>1 USA</p>
    </td>
    <td>Total: 
     <italic>n</italic> = 6680 LF pos. 
     <italic>n</italic> = 1734
    </td>
    <td>
     <p>Adults</p>
     <p>Pregnant women</p>
     <p>Children, Infants, Neonates</p>
     <p>(0 to &gt; 65 years old)</p>
    </td>
    <td>
     <p>Clinical presentation, symptoms (
      <italic>n</italic> = 15)
     </p>
     <p>LF fatality rate (
      <italic>n</italic> = 11)
     </p>
     <p>Biochemical laboratory parameters (
      <italic>n</italic> = 7)
     </p>
    </td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>Transmission and prevention</td>
    <td>12</td>
    <td>
     <p>5 Sierra Leone</p>
     <p>4 Nigeria</p>
     <p>1 Germany</p>
     <p>1 Liberia</p>
     <p>1 UK</p>
     <p>1 USA</p>
    </td>
    <td>Total: 
     <italic>n</italic> = 1980 LF pos: 
     <italic>n</italic> = 281
    </td>
    <td>
     <p>Adults</p>
     <p>Pregnant women</p>
     <p>Children, Infants, Neonates</p>
     <p>(0 to 73 years)</p>
    </td>
    <td>
     <p>Ribavirin as PEP (
      <italic>n</italic> = 4)
     </p>
     <p>Risk of nosocomial transmission (
      <italic>n</italic> = 5)
     </p>
    </td>
    <td>Ribavirin</td>
   </tr>
   <tr>
    <td>Diagnostics</td>
    <td>7</td>
    <td>
     <p>4 Sierra Leone</p>
     <p>2 Liberia</p>
     <p>1 Nigeria</p>
    </td>
    <td>Total: 
     <italic>n</italic> = 3338 LF pos: 
     <italic>n</italic> = 897
    </td>
    <td>
     <p>Adults</p>
     <p>Children</p>
    </td>
    <td>
     <p>PCR for diagnostics (
      <italic>n</italic> = 3) PCR and hybridization (
      <italic>n</italic> = 1)
     </p>
     <p>LFI, ELISA and PCR (
      <italic>n</italic> = 1)
     </p>
     <p>IgM as early marker (
      <italic>n</italic> = 1)
     </p>
    </td>
    <td>PCR, LFI, ELISA, virus isolation</td>
   </tr>
   <tr>
    <td>Immune response</td>
    <td>5</td>
    <td>
     <p>2 Guinea</p>
     <p>2 Sierra Leone</p>
     <p>1 Liberia</p>
     <p>1 Mali</p>
    </td>
    <td>Total: 
     <italic>n</italic> = 4570 LF pos: 
     <italic>n</italic> = 1437
    </td>
    <td>
     <p>Adults</p>
     <p>Children, Infants</p>
     <p>(7 months to 83 years)</p>
    </td>
    <td>
     <p>Levels of inflammatory cytokines chemokines and other pro-inflammatory mediators (
      <italic>n</italic> = 1)
     </p>
     <p>Prevalence of LASV-specific IgG antibodies (LV IgG) (
      <italic>n</italic> = 1)
     </p>
     <p>Population LF seroconversion (
      <italic>n</italic> = 1)
     </p>
    </td>
    <td/>
   </tr>
   <tr>
    <td>Drug therapy and supportive care</td>
    <td>10</td>
    <td>
     <p>4 Nigeria</p>
     <p>4 Sierra Leone</p>
     <p>2 USA</p>
     <p>1 Germany</p>
    </td>
    <td>Total: 
     <italic>n</italic> = 1516 LF pos: 
     <italic>n</italic> = 792
    </td>
    <td>
     <p>Adults</p>
     <p>Pregnant women</p>
     <p>Children, Infants, Neonates</p>
     <p>(0 to 65 years)</p>
    </td>
    <td>
     <p>Therapeutic effectiveness of Ribavirin (
      <italic>n</italic> = 9)
     </p>
     <p>Therapeutic effectiveness of LF convalescent plasma therapy (
      <italic>n</italic> = 2)
     </p>
     <p>Ribavirin treatment adverse event (
      <italic>n</italic> = 1)
     </p>
    </td>
    <td>
     <p>Ribavirin iv.</p>
     <p>Ribavirin oral</p>
     <p>Convalescent plasma</p>
    </td>
   </tr>
   <tr>
    <td>Risk factors for more severe disease</td>
    <td>4</td>
    <td>
     <p>3 Sierra Leone</p>
     <p>2 Guinea</p>
    </td>
    <td>Total: 
     <italic>n</italic> = 2110 LF pos. or probable: 
     <italic>n</italic> = 562
    </td>
    <td>
     <p>Adults</p>
     <p>Pregnant women Children, Infants, Neonates</p>
     <p>(0 to &gt; 60 years)</p>
    </td>
    <td>
     <p>Correlation of cytokine levels and outcome (
      <italic>n</italic> = 2)
     </p>
     <p>Correlation of AST and outcomes (
      <italic>n</italic> = 1)
     </p>
     <p>Correlation of BUN, ALP, ALT, and outcomes (
      <italic>n</italic> = 1)
     </p>
     <p>Correlation of viremia level and outcome (
      <italic>n</italic> = 1)
     </p>
     <p>Risk factors for positive LASV IgG (
      <italic>n</italic> = 1)
     </p>
    </td>
    <td/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations</italic>: 
   <italic>LF</italic> Lassa fever, 
   <italic>LASV</italic> Lassa virus, 
   <italic>Pos</italic> positive, 
   <italic>PEP</italic> post-exposure prophylaxis, 
   <italic>PCR</italic> polymerase chain reaction, 
   <italic>LFI</italic> lateral flow immunoassay, 
   <italic>ELISA</italic> enzyme-linked immunosorbent assay, 
   <italic>Ig</italic> immunoglobulin, 
   <italic>AST</italic> aspartate aminotransferase, 
   <italic>BUN</italic> blood urea nitrogen, 
   <italic>ALP</italic> alkaline phosphatase, 
   <italic>ALT</italic> alanine aminotransferase
  </p>
  <p>*Some studies were set in more than one country</p>
 </table-wrap-foot>
</table-wrap>
